Cyclopharm Statistics

Total Valuation

Cyclopharm has a market cap or net worth of AUD 236.72 million. The enterprise value is 213.40 million.

Market Cap	236.72M
Enterprise Value	213.40M

Important Dates

The next estimated earnings date is Monday, February 24, 2025.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Cyclopharm has 111.14 million shares outstanding. The number of shares has increased by 2.93% in one year.

Current Share Class	n/a
Shares Outstanding	111.14M
Shares Change (YoY)	+2.93%
Shares Change (QoQ)	+2.49%
Owned by Insiders (%)	8.14%
Owned by Institutions (%)	13.83%
Float	59.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.39
PB Ratio	4.98
P/TBV Ratio	5.66
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-22.91
EV / Sales	8.87
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.80

Financial Position

The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.12.

Current Ratio	4.38
Quick Ratio	3.34
Debt / Equity	0.12
Debt / EBITDA	n/a
Debt / FCF	-0.44
Interest Coverage	-62.09

Financial Efficiency

Return on equity (ROE) is -22.59% and return on invested capital (ROIC) is -18.88%.

Return on Equity (ROE)	-22.59%
Return on Assets (ROA)	-15.37%
Return on Capital (ROIC)	-18.88%
Revenue Per Employee	276,502
Profits Per Employee	-107,075
Employee Count	87
Asset Turnover	0.42
Inventory Turnover	1.11

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +12.70% in the last 52 weeks. The beta is 0.72, so Cyclopharm's price volatility has been lower than the market average.

Beta (5Y)	0.72
52-Week Price Change	+12.70%
50-Day Moving Average	1.70
200-Day Moving Average	1.57
Relative Strength Index (RSI)	70.83
Average Volume (20 Days)	158,019

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cyclopharm had revenue of AUD 24.06 million and -9.32 million in losses. Loss per share was -0.10.

Revenue	24.06M
Gross Profit	13.82M
Operating Income	-13.94M
Pretax Income	-9.01M
Net Income	-9.32M
EBITDA	-12.98M
EBIT	-13.94M
Loss Per Share	-0.10

Full Income Statement

Balance Sheet

The company has 28.89 million in cash and 5.57 million in debt, giving a net cash position of 23.32 million or 0.21 per share.

Cash & Cash Equivalents	28.89M
Total Debt	5.57M
Net Cash	23.32M
Net Cash Per Share	0.21
Equity (Book Value)	47.55M
Book Value Per Share	0.43
Working Capital	36.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -12.17 million and capital expenditures -527,088, giving a free cash flow of -12.70 million.

Operating Cash Flow	-12.17M
Capital Expenditures	-527,088
Free Cash Flow	-12.70M
FCF Per Share	-0.11

Full Cash Flow Statement

Margins

Gross margin is 57.47%, with operating and profit margins of -57.95% and -38.72%.

Gross Margin	57.47%
Operating Margin	-57.95%
Pretax Margin	-37.45%
Profit Margin	-38.72%
EBITDA Margin	-53.95%
EBIT Margin	-57.95%
FCF Margin	n/a

Dividends & Yields

Cyclopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.93%
Shareholder Yield	-2.93%
Earnings Yield	-4.62%
FCF Yield	-5.36%

Dividend Details

Stock Splits

The last stock split was on May 28, 2012. It was a reverse split with a ratio of 0.2.

Last Split Date	May 28, 2012
Split Type	Reverse
Split Ratio	0.2

Scores

Cyclopharm has an Altman Z-Score of 6.35.

Altman Z-Score	6.35
Piotroski F-Score	n/a